Noveome Biotherapeutics, formerly Stemnion

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Noveome Biotherapeutics, formerly Stemnion sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 1 currently recruiting 8 completed early-phase tilt top decile by trial count

Noveome Biotherapeutics, formerly Stemnion: 12 sponsored US clinical trials, 1 recruiting.

Noveome Biotherapeutics, formerly Stemnion sponsors 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye Syndrome, with 1 trials.

Top-decile sponsor footprint

Noveome Biotherapeutics, formerly Stemnion ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 21/100

8 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 1

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis

NCT06315738
TERMINATED Phase 2

ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects

NCT05066698
COMPLETED Phase 1

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

NCT04720378
COMPLETED Phase 1

Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects

NCT03901781
COMPLETED Phase 2

ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects

NCT03687632
COMPLETED Phase 2

Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

NCT02978183
COMPLETED Phase 2

Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis

NCT02761993
COMPLETED Phase 1

Study of ST266 Eye Drops in Treating Dry Eye

NCT02369861
COMPLETED Phase 1

Treatment of Human Gingivitis With Amnion-derived Cellular Cytokine Solution (ACCS)

NCT02071199
COMPLETED Phase 1

Study of ST266 Versus Saline in Treating Skin Irritation From Radiation

NCT01714973
TERMINATED Phase 2

Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts

NCT01715012
TERMINATED Phase 1

ST266 Versus Standard Care In Treating Partial Thickness Burns

NCT00886470

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 5

Therapeutic Areas

Dry Eye Syndrome 1
Necrotizing Enterocolitis 1
Ocular Hypertension 1

What is open in the Noveome Biotherapeutics, formerly Stemnion pipeline

1 recruiting of 12 indexed (8% open); 8 completed (67%).

Phase mix: 0 late (III/IV) vs 12 early (I/II) (early-phase heavy).

Top condition: Dry Eye Syndrome (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Noveome Biotherapeutics, formerly Stemnion: open-pipeline peers nationwide

Peers matched on 12 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Noveome Biotherapeutics, formerly Stemnion sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10152025 0%5%10%15%20% Total trials Recruiting share Noveome Biotherapeutics, formerly StemnionAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsAcrotech BiopharmaAtlanta VA Medical CenterBeacon TherapeuticsBoston VA Research Institute
Noveome Biotherapeutics, formerly Stemnion sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Noveome Biotherapeutics, formerly Stemnion sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Noveome Biotherapeutics, formerly Stemnion page

12 registered trials is a research-attention snapshot, not an endorsement of Noveome Biotherapeutics, formerly Stemnion or any single study.

  • 1 of Noveome Biotherapeutics, formerly Stemnion's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Dry Eye Syndrome is the condition Noveome Biotherapeutics, formerly Stemnion studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye Syndrome trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Noveome Biotherapeutics, formerly Stemnion pipeline card: 12 registered trials from official public datasets.Report a data error.